期刊文献+

^(18)F-FDG和^(18)F-FLT PET/CT在肺部良恶性肿瘤鉴别诊断中的价值 被引量:7

The vlue of ^(18)F-FDG and ^(18)F-FLT PET imaging for differential diagnosing pulmonary tumour
下载PDF
导出
摘要 目的:分析18F-FDG(18F-脱氧葡萄糖)和18F-FLT(18F-胸腺嘧啶)两种显像剂的PET/CT检查在肺部肿瘤中的不同影像学表现,提高PET/CT在肺部良恶性肿瘤鉴别诊断中价值,从而为临床治疗方案的选择提供可靠依据。方法:收集肺肿瘤患者55例为研究对象,其中男性33例,女性22例,年龄17~82岁,28例为肺内孤立肿块,其余为2~3个肿块,肿块大小0.6~11.0cm,所有患者均行肺部18 F-FDG和18 F-FLT PET/CT检查,分析18 F-FDG和18 F-FLT标准摄取值(SUV)与肺肿瘤患者的年龄、肿块大小及病理类型等相互关系和统计学意义。结果:18 F-FDG和18 F-FLT PET/CT的SUV与肺肿瘤患者的年龄、肿块大小均无统计学差异(P>0.05),18 F-FDG PET/CT的SUV与患者的病理类型亦无统计学差异(P>0.05),而18F-FLT PET/CT的SUV与患者的病理类型有统计学差异(P<0.05)。结论:肺肿瘤患者的肿块病理类型是影响18F-FLT PET/CT的SUV的重要因素,18F-FLT PET/CT的SUV在肺部良恶性肿瘤鉴别诊断中具有重要的价值。 Objective:The study aims were to investigate the diagnostic performance of dual-tracer ( 18F- fluorodexyglu- cose 18F-FDG] and 18F-fluorothymidine 18F-FL 18PET/CT in pulmonary nodules, to differentiate the malignant tissue from benign pulmonary nodules. Methods:Fifty-five patients were chose in our study, in which 28 had one pulmonary nod- ule only, others had more than two pulmonary nodules, with the diameter of pulmonary nodule from 0.6 to l1. 0 centime- ters. All the patients underwent 18F-FDG and lSF-FLT PET/CT and the maximal standardized uptaken value (SUV) of 18F-FDG or 18F-FLT were determined. PET/CT resultes were correlated with age. diameter of the nodule, and his- topathologic types. Results There were no significant differences between the SUV of lSF-FDG and age, diameter of the nodule, type of the pathologic nature of nodule of all fifty-five patients ( P 〉0.05). Otherwise, there were significant differences between the SUV of 18F-FLT and the type of pathologic nature of nodules of all fifty-five patients ( P〉0.05). Conclusion:The study shows that 18F-FLT PET/CT SUV can accurately differentiate segments with carcinoma from be- nign nodules.
出处 《医学影像学杂志》 2011年第12期1819-1822,共4页 Journal of Medical Imaging
关键词 18F-脱氧葡萄糖 18F-胸腺嘧啶 正电子发射计算机断层扫描仪 标准摄取值 肺肿瘤 鉴别诊断 18F-fluorodeoxyglucose 18F-fluorothymidine Positron emission tomography / Computed tomography Standardized uptake value~ Pulmonary turnout Differential diagnosis
  • 相关文献

参考文献11

  • 1Garcia Vicente AM,Castrejón AS,León Martín AA.et al.Value of 4-Dimensional 18F-FDG PET/CT in the classification of pulmonary lesions[J].J Nucl Med Technol,2011,39:91-99.
  • 2Khan N,Islam MM,Mahmood S,et al.18 F-Fluorodcoxyglucose uptake in tumor[J].Mymensingh Med J,2011,20:332-342.
  • 3Yap CS,Czernin J,Fishbein MC,et al.Evaluation of thoracic tumor with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography[J].Chest,2006,129:393-401.
  • 4Yamamoto Y,Nishiyama Y,Ishikawa S,et al.Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer[J].Eur J NuclMed Mol Imaging,2007,34:1610-1616.
  • 5Sathekge M,Maes A,Kgomo M,et al.Use of 18F-FDGPET to predict response to first-line tuberculostatics in HIVassociated tuberculosis[J].J Nucl Med,2011,52:880-885.
  • 6Mier W,Haherkorn U,Eisenhut M.18F-FLT:portrait of a proliferation marker[J].Eur J Nucl Med,2002,29:165-169.
  • 7Weber WA.Monitoring tumor response to therapy with 18FFLT PET[J].J Nucl Med,2010,51:841-844.
  • 8Hashimoto Y,Tsujikawa T,Kondo C,et al.Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5[J].J Nucl Med,2006,47:426-431.
  • 9Hatt M,Cheze-Le Rest C,Aboagye EO,et al.Reproducibility of 18F-FDG and 3-deoxy-3-18 F-fluorothymidine PET tumor volume measurements[J].J Nucl Med,2010,51:1368-1376.
  • 10Frings V,de Langen AJ,Smit EF,et al.Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer[J].J Nucl Med,2010,51:1870-1877.

同被引文献45

  • 1辛军,赵周社,吴先衡,齐如海,吴文凯,郭启勇.评价双时相^(18)F-FDG PET/CT显像对肺结节临床诊断的价值[J].中国临床医学影像杂志,2012,23(11):785-788. 被引量:6
  • 2陈翼,马黎明.PET显像仪的类型及临床应用[J].医学影像学杂志,2006,16(2):202-204. 被引量:6
  • 3吴华伟,路青,程杰军,许建荣,戈欣,李磊.肺部疾病背景抑制磁共振扩散成像的参数优化[J].中国医学计算机成像杂志,2007,13(1):26-31. 被引量:22
  • 4Susannah J,Elizabeth H,Weng N,et al. Estimation of an optimal chemotherapy utilisation rate for lung cancer:an evidence-based benchmark for cancer care [J]. Lung Cancer, 2010,69 (3) :307-314.
  • 5Prunella B,Mahmood A,Vlatka D,et al. Patients" preferences forchemotherapy in non-small-cell lung cancer:a systematic review [J]. Lung Cancer, 2010,69 (2) : 141-147.
  • 6Debra PR, Nikki MC,Thomas D,et al. Patterns and predictors of first- line chemotherapy use among adult.s with advanced non-small cell lung cancer in the cancer research network [J]. Lung Cancer, 2012,78(3) :245-252.
  • 7Etta V,Maria PS,Aaron IV. Measuring the relationship of quality of life and health status,includin: tumor hurden,symptoms,and bio- chemical measures in patients with neuroendocrine tumors [J]. En- docrinology and Metabolism Clinics of North America,2011,40 ( 1 ) : 97-109.
  • 8Patricia AP,Richard S,Bryan F,et al. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tu- mors undergoing open,laparoscopic and nephron sparing surgery [J]. The Journal of Urology, 2012,187 (3) : 822-826.
  • 9Stephanie EC,Thomas W,Kerstin K,et al. Hearing preservation after radiotherapy for vestibular schwannomas is comparable to hearing de- terioration in healthy adults and is accompanied by local tumor con- trol and a highly preserved quality of life (QOL)as patients" self-re- ported outcome [J]. Radiotherapy and Oncology,2013,106 (2) : 175- 180.
  • 10Khan N, Islam MM, Mahmood S, et al. 18F-FDG uptake in tumor[J]. Mymensingh Med J, 2011, 20: 332-342.

引证文献7

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部